Skip to main content

Table 1 Characteristics and clinical outcome of patients undergoing pancreatic surgery before and during the COVID lockdown period.Ordinal data presented as median (25;75 quartiles)

From: Pancreatic surgery during the COVID-19 pandemic 2020–2021: an observational cohort study from a third level referral center

  Before lockdown   
  2017/2018 2018/2019 2019/2020 Total Lockdown p value
Numbers 254 253 232 739 242 0.851
Males/females 153/101 137/116 123/109 415/326 140/102  
Age, years 69 (62;73) 67 (58;73) 69 (61;74) 68 (60;73) 68 (59;75) 0.140
ASA (%)       
1–2 123 (48.4) 141 (55.7) 92 (39.7) 356 (48.2) 101 (41.7) 0.088
3 129 (50.8) 111 (43.9) 139 (59.9) 379 (51.3) 141 (58.3) 0.064
4 2 (0.8) 1 (0.4) 1 (0.4) 4 (0.5) 0 0.577
Charlson score (%)
0–1 160 (63.0) 161 (63.6) 147 (63.4) 468 (63.3) 139 (57.4) 0.110
2–3 69 (27.2) 74 (29.3) 60 (25.9) 203 (27.5) 73 (52.5) 0.412
 > 3 25 (9.9) 18 (7.1) 25 (10.8) 68 (9.2) 30 (12.4) 0.174
Waiting time (days)
All patients 31 (24;39) 29 (21;41) 28 (20;36) 30 (21;39) 29 (21;37) 0.895
Malignant tumor 31 (23;37) 28 (19;39) 27 (20;35) 28 (21;37) 28 (21;35) 0.294
NET 27 (13;32) 32 (24;42) 34 (26;42) 30 (24;40) 38 (25;52) 0.076
Benign disease 33 (29;45) 39 (24;49) 29 (20;41) 32 (23;46) 38 (20;65) 0.134
Length of stay (days)* 10 (7;17)   10 (7;17) 10 (8;16) 10 (7;17) 11 (6;18)
30-day mortality (%) 5 (2.0) 4 (1.6) 3 (1.3)12 (1.6) 5 (2.1) 0.582  
90-days mortality (%) 14 (5.5) 13 (5.1) 12 (5.2)39 (5.3) 18 (7.4) 0.209  
In-hospital deaths (%) 5 (2.0) 4 (1.6) 3 (1.3) 12 (1.6) 5 (2.1) 0.582  
  1. *In-hospital deaths excluded